1.725USD-1.15%Mkt Cap: 227.10M USDP/E: —Last update: 2026-06-01
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH)…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap227.10M USD
Enterprise Value127.87M USD
Revenue (TTM)—
Gross Profit1.01M USD
Net Income (TTM)-48.26M USD
Revenue/Share—
Last Price1.725 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS45719W1062
Valuation
P/E (Trailing)—
P/E (Forward)-4.61
PEG—
EV/EBITDA-2.65
EV/Revenue—
P/S—
P/B1.72
EPS (TTM)-0.44
EPS (Forward)-0.38
52W Range
1.33042% of range2.260
52W High2.260 USD
52W Low1.330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-27.91%
ROA-26.63%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.79M USD
CapEx (TTM)452.02K USD
FCF Margin—
FCF Yield-6.59%
Net Debt-170.37M USD
Net Debt/EBITDA3.52
Balance Sheet
Debt/Equity0.00
Current Ratio30.14
Quick Ratio29.83
Book Value/Sh1.017 USD
Cash/Share1.000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 30, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)6.000 USD
Target Range3.000 USD – 8.000 USD
# Analysts7
Ownership
Shares Out.132.03M
Float86.88M
Insiders6.42%
Institutions93.30%
Short Interest
Short Ratio20.1d
Short % Float21.55%
Short % Out.13.40%
Shares Short17.69M
Short (prev mo.)17.79M
Technical
SMA 501.788 (-3.5%)
SMA 2001.707 (+1.1%)
Beta0.96
S&P 52W Chg27.94%
Avg Vol (30d)785.83K
Avg Vol (10d)785.55K
Technical Indicators
RSI (14)46.9
MACD-0.0359
MACD Signal-0.0262
MACD Hist.-0.0096
BB Upper2.119 USD
BB Middle1.825 USD
BB Lower1.530 USD
BB Width32.32%
ATR (14)0.1018 USD
Vol Ratio (20d)0.28x